Black Diamond Therapeutics announces 2022 annual meeting voting results

Black Diamond Therapeutics, Inc.

Three Class II directors elected: Ali Behbahani (18.2M for), Garry Menzel (18.6M for), Samarth Kulkarni (21.8M for).
PricewaterhouseCoopers LLP ratified as auditor for FY2022 with 30.1M for, 14k against, 55k abstain.
Quorum of 30.2M shares out of 36.3M outstanding was present at the June 7, 2022 virtual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.